期刊
NANOMEDICINE
卷 7, 期 2, 页码 185-197出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.11.131
关键词
antisense oligonucleotides targeted to MDR1 and BCL2 mRNA cisplatin; doxorubicin; LHRH receptor-specific targeting; liposomes; multicomponent nanosystem; primary and metastatic ovarian cancer; suppression of drug resistance
资金
- National Cancer Institute [R01 CA 100098, R01 CA 138533]
- National Institute of Environmental Health Sciences at the NIH [T32 ES007148]
- National Science Foundation [CBET-0933966]
Aims: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects. Materials & Methods: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma. Results: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects. Conclusions: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据